Logo

olaparib

AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
Premium

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Repare Therapeutics Shuffles Pipeline, Pauses Some Programs Pending Partnership

The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients
Premium

Prostate cancer patients with BRCA2 and other homologous recombination repair mutations fared better on Lynparza than those without genomic alterations.

European Commission Approves AstraZeneca's Imfinzi Regimens Based on MMR Status

Depending on MMR status, endometrial cancer patients can receive first-line therapy with Imfinzi and chemo followed by Imfinzi alone or Imfinzi with Lynparza.

Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium

The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.

Jul 30, 2024

Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates

Jul 25, 2024

AstraZeneca Reports Encouraging Uptake of New Breast Cancer Drug Truqap in First Half of 2024
Premium

Jul 1, 2024

CHMP Recommends AstraZeneca's Imfinzi, Lynparza for Endometrial Cancer Based on MMR Status

May 23, 2024

Tango Therapeutics Scraps USP1 Inhibitor Trial Due to Toxicities

May 10, 2024

Chinese Trial Suggests PARP, VEGF Inhibitor Combo Benefits Advanced BRCA1/2-Mutant Breast Cancer
Premium

Apr 25, 2024

AstraZeneca Looks to Bolster Radiopharmaceutical Capacity as Cancer Drugs Help Q1 Revenue Growth
Premium

Apr 10, 2024

PARP Inhibitor, Chemo Combo Shows Potential as Neoadjuvant Option for BRCA-Mutant Breast Cancer
Premium

Mar 21, 2024

TAPUR Results Support Lynparza's Activity in BRCA1/2-Mutant Pancreatic Cancer
Premium

Feb 8, 2024

AstraZeneca Discusses Plans for New CAR T-Cell Assets; Posts Strong Oncology Rx Sales in Q4
Premium

Feb 1, 2024

Keytruda Revenues Grow 21 Percent in Q4 as Merck Focuses on Diversifying Oncology Pipeline

Jan 30, 2024

Adjuvant Lynparza Is Cost Effective in BRCA1/2-Mutant Breast Cancer Analysis
Premium

Jan 3, 2024

Tango Therapeutics Begins Phase I/II Trial of TNG348 in BRCA1/2-Mutant, HRD-Positive Cancers

Oct 26, 2023

Keytruda Sales Grow 17 Percent in Q3 as Merck Tees Up Combination Therapy Strategy
Premium

Aug 25, 2023

AstraZeneca Goes to Court Over Inflation Reduction Act, Arguing Price Controls Stymie Orphan Drugs

Jun 21, 2023

FDA Approves Pfizer's Talzenna, Xtandi for HRR-Mutant Advanced Prostate Cancer

Jun 7, 2023

NICE Recommends Lynparza for BRCA1/2-Mutant Ovarian Cancer After Two Rounds of Chemotherapy

Jun 6, 2023

ASCO Data Bolster Talzenna, Xtandi Benefit in HRR-Mutant mCRPC as Pfizer Pursues Allcomers Approval
Premium

Jun 3, 2023

Ovarian Cancer Patients Without BRCA Mutations Benefit From Lynparza, Imfinzi Plus Standard of Care
Premium

Jun 1, 2023

FDA Approves Merck, AstraZeneca's Lynparza Combo for BRCA-Mutant Metastatic Prostate Cancer

Jun 1, 2023

NCI Launches Platform Trial to Test Biomarker-Informed Combination Therapies
Premium